Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum.
about
Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality DisorderSchizotypal personality disorder: a current review.Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112.Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.Psychiatric comorbidity and the persistence of drug use disorders in the United States.Tracking the impact of translational research in psychiatry: state of the art and perspectivesCognition in schizophrenia: core psychological and neural mechanisms.Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia.Genetics of cognitive control: Implications for Nimh's research domain criteria initiative.Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia.Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease.Cognitive impairments in psychotic disorders: common mechanisms and measurement.
P2860
Q28385659-6D33A35E-C508-4613-A4C4-944B80A1F011Q29038503-729CCA26-4BD4-48E0-B53D-60CF583588B1Q34279024-746A6BF5-33E9-4D5F-93F6-92ED47A2C897Q34325076-CB28C2BA-EE99-4A05-B3D1-ECF7070F20E7Q34703195-FA7DB101-A7D5-4C5E-B61D-0C08C4BD8B6AQ35678302-DF592C55-4EBD-40D3-B92B-3659775C3789Q36498636-A6110519-4D8B-4CBD-8AC3-7D2754124007Q37387648-14F958DF-FE4F-4259-9922-8C851FCFAA30Q37945156-5D1FCDA4-AA3A-4593-99BB-902991E62B82Q38697005-82415556-ED3B-4344-A57C-81D10C86B941Q38762256-0965248D-01AB-4CF9-9E87-D86AC1678EFEQ42367850-0B4236B5-7271-4945-BE24-CCC3C319795EQ42515523-0B334ED3-DF0C-4B65-8825-8652EE1B65DCQ42973967-7BDA9B2D-15FF-42E3-B068-AE7AFA8FD0CC
P2860
Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@ast
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@en
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@nl
type
label
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@ast
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@en
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@nl
prefLabel
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@ast
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@en
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@nl
P2093
P2860
P356
P1476
Pergolide treatment of cogniti ...... in the schizophrenia spectrum.
@en
P2093
Antonia New
Harold W Koenigsberg
Janine D Flory
Joseph Triebwasser
Larry J Siever
Larry J Sprung
Margaret M McClure
Marianne Goodman
P2860
P2888
P304
P356
10.1038/NPP.2010.5
P407
P577
2010-02-03T00:00:00Z
P5875
P6179
1021199339